Nurix Therapeutics: Redmile's $63M Vote of Confidence

On February 17, 2026, Redmile Group disclosed a major purchase of 4,415,514 Nurix Therapeutics shares worth approximately $63.43 million. This significant acquisition came despite Nurix stock declining 6.5% over the past year and underperforming the S&P 500 by 23 percentage points.

The transaction increased Redmile's total Nurix position value to $153.54 million, making it the fund's third-largest holding at 11.3% of its $1.36 billion portfolio. This substantial commitment places Nurix alongside other biotech favorites in Redmile's top holdings, including SRRK and KRYS.

Nurix currently trades at $15.64 with a market capitalization of $1.37 billion. The company reported $84 million in trailing revenue but continues to invest heavily in research, resulting in a $264 million net loss over the past twelve months.

The biotech firm specializes in developing small molecule therapies for cancer and immune disorders, with key programs targeting BTK degradation and CBL-B inhibition. Its pipeline includes several clinical-stage candidates and partnerships with major pharmaceutical companies like Gilead Sciences and Sanofi.

Redmile's substantial investment signals strong institutional belief in Nurix's long-term potential, particularly noteworthy given the stock's recent underperformance. When a sophisticated biotech fund increases its position to over 11% of assets, it suggests deep conviction in the company's scientific approach and clinical prospects.

The timing coincides with Nurix advancing its lead BTK degrader into registrational trials, supported by promising Phase 1 data showing an 83% objective response rate. This clinical progress represents a potential inflection point for the company's valuation if successful.

Nurix's financial position appears solid with $592.9 million in cash, providing runway for continued clinical development. The company recently raised $250 million through an equity offering, demonstrating continued market access despite operational losses.

For biotech investors, this transaction highlights the sector's high-risk, high-reward nature. While near-term stock performance has been weak, Redmile's bet suggests they see substantial upside if Nurix's clinical programs deliver positive results in upcoming trials.